GERMANTOWN, Md., March 18, 2021 — Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS)...
treatment News
Beijing, China – Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults and is poorly controlled. Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression, and co-targeting of CSF1R and VEGFR is likely to be an effective strategy for GBM...
Boston, MA — To help prevent preeclampsia and preterm birth—common complications in pregnancy that can be fatal to women and newborns—low-dose calcium supplementation (equivalent to one 500-milligram pill per day) may be as effective as the World Health Organization (WHO)’s recommended high-dose calcium supplementation (equivalent to three 500-milligram pills taken...
Despite taking medication, many epileptic children still suffer from associated seizures. Now Saudi Arabian researchers might have undertaken the first steps to change this. Epileptic seizures are abnormal electrical discharges in the brain which are usually accompanied by sudden brief episodes of altered or diminished consciousness or convulsions. These do...
LAGUNA HILLS, Calif. — PreludeDx, a leader in precision diagnostics, has unveiled data from an analysis of over 700 early-stage invasive breast cancer patients for AidaBreast™ – a novel biosignature that predicts 10-year recurrence rate and radiation therapy (RT) benefit – at the 41st Annual Miami Breast Cancer Conference (MBCC)....
Boston, MA — Infants born to women with pre-gestational type 2 diabetes who take second-line non-insulin antidiabetic medications (ADMs) during pregnancy are at no higher risk of major congenital malformations (MCMs) than infants born to those who take insulin, according to a new study led by Harvard T.H. Chan School...
Could a holiday in the sun reduce the risk of developing multiple sclerosis? In a recent review for F1000 Medicine Reports, Bridget Bagert and Dennis Bourdette highlight recent advances in potential treatments. Multiple sclerosis (MS) results from a failure of the body to recognize itself. The immune system attacks and...
CHESHIRE, Conn. — Clinical investigators observed that Soliris(R) (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), reduced hemolysis (red blood cell destruction) and improved symptoms in nine patients with paroxysmal nocturnal hemoglobinuria (PNH) who had received no blood transfusions prior to initiating Soliris therapy. In...
The XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of ALTUVIIIO as once-weekly prophylaxis in previously treated patients <12 years of age with severe hemophilia A met its primary endpoint of safety, with no FVIII inhibitors detected in 74 children, with more than 50 children experiencing at least 50 exposure days, nearly a full year of treatment.
KIRKLAND, Wash — Prevencio, Inc., the AI-Powered Blood Test Company, today announces the presentation of data using its Artificial Intelligence (AI) driven HART CVE blood test for prediction of subsequent adverse cardiac events in prostate cancer patients undergoing radiotherapy and androgen deprivation therapy. Researchers and clinicians from Emory Winship Cancer...